{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:31Z","timestamp":1790774671964,"version":"4.1.0"},"reference-count":226,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1053\/j.jvca.2026.02.035","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:49:29Z","timestamp":1772005769000},"page":"1806-1827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure"],"prefix":"10.1053","volume":"40","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2026.02.035_bib0001","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: Exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol Chem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0002","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/hsz-2019-0386","article-title":"The cGMP system: Components and function","volume":"401","author":"Hofmann","year":"2020","journal-title":"Biol Chem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0004","first-page":"439","article-title":"Cyclic strain increases endothelial nitric oxide synthase activity","volume":"116","author":"Awolesi","year":"1994","journal-title":"Surgery"},{"issue":"Pt 1","key":"10.1053\/j.jvca.2026.02.035_bib0005","doi-asserted-by":"crossref","first-page":"C757","DOI":"10.1152\/ajpcell.1995.269.3.C757","article-title":"Regulation of Ca(2+)-dependent nitric oxide synthase in bovine aortic endothelial cells","volume":"269","author":"Buckley","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0006","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.117.303776","article-title":"Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease","volume":"120","author":"Kraehling","year":"2017","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-540-68964-5_2","article-title":"Biochemistry of soluble guanylate cyclase","volume":"191","author":"Derbyshire","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0008","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follman","year":"2017","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0009","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cellsig.2007.06.017","article-title":"The alpha2beta1 isoform of guanylyl cyclase mediates plasma membrane localized nitric oxide signalling","volume":"19","author":"Bellingham","year":"2007","journal-title":"Cell Signal"},{"key":"10.1053\/j.jvca.2026.02.035_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"Derbyshire","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0183-2023","article-title":"The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: From PDE5 to soluble guanylate cyclase","volume":"33","author":"Benza","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0012","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: Past, present, and future","volume":"181","author":"Sandner","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1053\/j.jvca.2026.02.035_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Handb Exp Pharmacol"},{"issue":"Suppl 1","key":"10.1053\/j.jvca.2026.02.035_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0016","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0017","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FJC.0000000000000817","article-title":"Targets of cGMP\/cGKI in cardiac myocytes","volume":"75","author":"Adler","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0018","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.98.2.735","article-title":"Myoglobin: A scavenger of bioactive NO","volume":"98","author":"Flogel","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2026.02.035_bib0019","doi-asserted-by":"crossref","first-page":"21761","DOI":"10.1074\/jbc.M302573200","article-title":"Myoglobin protects the heart from inducible nitric oxide synthase (iNOS)-mediated nitrosative stress","volume":"278","author":"Godecke","year":"2003","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"10.1053\/j.jvca.2026.02.035_bib0020","first-page":"H1568","article-title":"Nitric oxide does not modulate myocardial contractility acutely in in situ canine hearts","volume":"270","author":"Crystal","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0021","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-642-38664-0_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0022","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.chest.2016.05.024","article-title":"Riociguat: Mode of action and clinical development in pulmonary hypertension","volume":"151","author":"Ghofrani","year":"2017","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.02.035_bib0024","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2019,5\u2019-cyclic nucleotide phosphodiesterases: Inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.jvca.2026.02.035_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/FJC.0000000000000749","article-title":"Blanton RM. cGMP signaling and modulation in heart failure","volume":"75","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/jmcc.2000.1334","article-title":"Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart","volume":"33","author":"Paolocci","year":"2001","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0027","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1172\/JCI200314172","article-title":"Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension","volume":"111","author":"Landmesser","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.02.035_bib0028","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1172\/JCI21968","article-title":"Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathological remodeling from chronic pressure overload","volume":"115","author":"Takimoto","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.02.035_bib0029","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/CIRCRESAHA.111.259242","article-title":"Pressure-overload-induced subcellular relocalization\/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation","volume":"110","author":"Tsai","year":"2012","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.02.035_bib0032","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0033","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0034","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0735-1097(96)00241-0","article-title":"C-type natriuretic peptide-mediated coronary vasodilation: Role of coronary nitric oxide and particulate guanylate cyclase systems","volume":"28","author":"Wright","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.HYP.37.4.1179","article-title":"C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels","volume":"37","author":"Honing","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.02.035_bib0036","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-CGMP signalling: Lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0037","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0039","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","article-title":"Effect of YC-1, and NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators","volume":"120","author":"Mulsch","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0041","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0042","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.CIR.0000144469.01521.8A","article-title":"Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs","volume":"110","author":"Evgenov","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0043","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0044","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1440-1681.2007.04524.x","article-title":"Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anesthetized dogs","volume":"34","author":"Freitas","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0045","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50634","article-title":"Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy","volume":"8","author":"Horst","year":"2019","journal-title":"Elife"},{"key":"10.1053\/j.jvca.2026.02.035_bib0046","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1053\/j.jvca.2026.02.035_bib0047","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52418","article-title":"Wedging open a catalytic site","volume":"8","author":"Beuve","year":"2019","journal-title":"Elife"},{"key":"10.1053\/j.jvca.2026.02.035_bib0048","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Cinaciguat, a soluble guanylate cyclase activator: Results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0049","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2026.02.035_bib0050","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J Hypertens"},{"key":"10.1053\/j.jvca.2026.02.035_bib0051","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5415 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0053","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/rccm.201311-2037OC","article-title":"Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema","volume":"189","author":"Weissmann","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0054","article-title":"Soluble guanylate cyclase stimulation reduces oxidative stress in experimental chronic obstructive pulmonary disease","volume":"5","author":"Paul","year":"2018","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073502","article-title":"Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension","volume":"8","author":"Becker","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0056","article-title":"Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding","volume":"2018","author":"Rai","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1053\/j.jvca.2026.02.035_bib0057","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: An ascending-dose study in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0058","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40262-017-0604-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of riociguat","volume":"57","author":"Frey","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0059","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1183\/09059180.00011112","article-title":"Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy","volume":"18","author":"Ghofrani","year":"2009","journal-title":"Eur Respir Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0060","first-page":"971","article-title":"Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension","volume":"10","author":"Belik","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0061","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanlyate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0062","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0063","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0064","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0074","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s40265-013-0149-5","article-title":"Riociguat: First global approval","volume":"73","author":"Conole","year":"2013","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0066","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0067","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0068","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0069","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: Switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0070","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0071","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/eurjhf\/hfs071","article-title":"Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): Rationale and design","volume":"14","author":"Ghio","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0072","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.02.035_bib0073","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0075","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1053\/j.jvca.2019.11.019","article-title":"Chronic thromboembolic pulmonary hypertension\u2014management strategies and outcomes","volume":"34","author":"Ranka","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.02.035_bib0076","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1016\/j.jacc.2013.10.024","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"62","author":"Kim","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0077","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.115.016522","article-title":"Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry","volume":"133","author":"Delcroix","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0078","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","article-title":"Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry","volume":"141","author":"Mayer","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2026.02.035_bib0079","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): Results from an international prospective registry","volume":"124","author":"Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0081","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0082","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029024","article-title":"Revised definition of pulmonary hypertension and approach to management: A clinical primer","volume":"12","author":"Maron","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.02.035_bib0083","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.healun.2015.02.003","article-title":"Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study","volume":"34","author":"D'Armini","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.02.035_bib0084","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/heartjnl-2016-309621","article-title":"Haemodynamic effects of riociguat in inoperable\/recurrent chronic thromboembolic pulmonary hypertension","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"key":"10.1053\/j.jvca.2026.02.035_bib0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(16)30022-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: Data from the CHEST-2 open-label, randomised, long-term extension trial","volume":"4","author":"Simonneau","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0086","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.rmed.2017.05.008","article-title":"Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study","volume":"128","author":"Halank","year":"2017","journal-title":"Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106220","article-title":"Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry","volume":"178","author":"Ghofrani","year":"2021","journal-title":"Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0088","doi-asserted-by":"crossref","first-page":"00230","DOI":"10.1183\/23120541.00230-2025","article-title":"Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat versus other medications: A COMPERA analysis","volume":"11","author":"Held","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0089","first-page":"435","article-title":"Group 4 pulmonary hypertension: chronic thromboembolic pulmonary hypertension: Epidemiology, pathophysiology, and treatment","volume":"34","author":"Kim","year":"2016","journal-title":"Cardiol Clin"},{"key":"10.1053\/j.jvca.2026.02.035_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0119-2016","article-title":"Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension","volume":"26","author":"Lang","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0091","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","article-title":"Chronic thromboembolic pulmonary hypertension: Evolving therapeutic approaches for operable and inoperable disease","volume":"71","author":"Mahmud","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0092","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): A multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study","volume":"10","author":"Jais","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0093","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","article-title":"Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR PBA): An open-label, randomised controlled trial","volume":"10","author":"Kawakami","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0094","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.124.068610","article-title":"Worldwide CTEPH registry: Long-term outcomes with pulmonary endarterectomy, balloon pulmonary angioplasty, and medical therapy","volume":"150","author":"Delcroix","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0095","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0096","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension. A review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.02.035_bib0097","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.healun.2014.12.001","article-title":"Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study","volume":"34","author":"Langleben","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.02.035_bib0098","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.healun.2016.12.012","article-title":"Comparison of hemodynamic parameters in treatment-naive and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study","volume":"36","author":"Galie","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.02.035_bib0099","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1136\/heartjnl-2015-307832","article-title":"Riociguat for pulmonary arterial hypertension associated with congenital heart disease","volume":"101","author":"Rosenkranz","year":"2015","journal-title":"Heart"},{"key":"10.1053\/j.jvca.2026.02.035_bib0100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.jvca.2026.02.035_bib0101","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018769305","article-title":"Riociguat treatment for portopulmonary hypertension: A subgroup analysis from the PATENT-1\/-2 studies","volume":"8","author":"Cartin-Ceba","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0102","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: Data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106241","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2021","journal-title":"Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0104","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018823715","article-title":"Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: Results from the phase 4 MOTION study","volume":"9","author":"Sood","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020942121","article-title":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)","volume":"10","author":"Ghofrani","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0106","article-title":"Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study","volume":"12","author":"Aguilar","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0107","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12337","article-title":"Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies","volume":"14","author":"Varian","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijcard.2015.05.105","article-title":"Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"195","author":"Marra","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0109","first-page":"1137","article-title":"Effects of riociguat on right ventricular remodelling in chronic thromboembolic pulmonary hypertension patients: A prospective study","volume":"34","author":"Ahmadi","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12931-018-0957-y","article-title":"Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)","volume":"19","author":"Marra","year":"2018","journal-title":"Respir Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0111","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.healun.2021.06.020","article-title":"Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"40","author":"Benza","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.02.035_bib0112","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000510860","article-title":"Clinical significance of guanlylate cyclase stimulator, riociguat, on right ventricular functional improvement in patients with pulmonary hypertension","volume":"146","author":"Murata","year":"2021","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2026.02.035_bib0113","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0061-2022","article-title":"Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"31","author":"Benza","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0114","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020963836","article-title":"Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies","volume":"10","author":"Thenappan","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40119-015-0046-y","article-title":"Early observations on the use of riociguat in a larger, metropolitan pulmonary arterial hypertension\/chronic thromboembolic pulmonary hypertension treatment center","volume":"4","author":"Sulica","year":"2015","journal-title":"Cardiol Ther"},{"key":"10.1053\/j.jvca.2026.02.035_bib0116","author":"Bayer"},{"key":"10.1053\/j.jvca.2026.02.035_bib0117","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0118","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0119","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0120","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1053\/j.jvca.2026.02.035_bib0121","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.rmed.2016.11.001","article-title":"Rational and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors","volume":"122","author":"Hoeper","year":"2017","journal-title":"Respir Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0122","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2020.05.044","article-title":"Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE","volume":"317","author":"Benza","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0123","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00408-018-0160-4","article-title":"Initial riociguat monotherapy and transition from sildenafil to riociguat in patients with idiopathic pulmonary arterial hypertension: Influence on right heart remodeling and right ventricular-pulmonary arterial coupling","volume":"196","author":"Taran","year":"2018","journal-title":"Lung"},{"key":"10.1053\/j.jvca.2026.02.035_bib0124","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70140","article-title":"Predicting response to switching from phosphodiesterase type 5 inhibitor to riociguat in patients with pulmonary arterial hypertension: Biomarker and responder analysis of the RESPITE and REPLACE studies","volume":"15","author":"Klinger","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0126","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: The haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0127","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/680214","article-title":"Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease","volume":"5","author":"Ghofrani","year":"2015","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.02.035_bib0129","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02445-2018","article-title":"Riociguat for treatment of pulmonary hypertension in COPD: A translational study","volume":"53","author":"Pichl","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.healun.2021.02.006","article-title":"Impact of lung morphology on clinical outcome with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post-hoc subgroup analysis of the RISE-IIP study","volume":"40","author":"Nathan","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.02.035_bib0131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044481","article-title":"The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertropy","volume":"7","author":"Irvine","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0132","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertension","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.02.035_bib0133","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083910","article-title":"Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: Insights from MRI\/PET imaging","volume":"8","author":"Methner","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/cvr\/cvt257","article-title":"NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size","volume":"101","author":"Bice","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.02.035_bib0136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021853","article-title":"Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats","volume":"6","author":"Geschka","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.02.035_bib0137","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/bph.15333","article-title":"Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodeling","volume":"179","author":"Rudebusch","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0138","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","volume":"149","author":"Xia","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.jvca.2026.02.035_bib0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: Results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0141","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40262-024-01384-1","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of vericiguat","volume":"63","author":"Fritsch","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0142","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cpt.2712","article-title":"Population pharmacokinetics of vericiguat in patients with heart failure with reduced ejection fraction: An integrated analysis","volume":"112","author":"Trujillo","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2026.02.035_bib0143","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","article-title":"Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: Results from preclinical and phase I healthy volunteer studies","volume":"59","author":"Boettcher","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40262-020-00935-6","article-title":"Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: Results from three randomized phase I studies in human volunteers","volume":"60","author":"Boettcher","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0145","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rational and design of the soluble guanylate cyclase stimulator in heart failure studies (SOCRATES)","volume":"16","author":"Piescke","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0151","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","article-title":"Soluble guanylate cyclase: A potential therapeutic target for heart failure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2026.02.035_bib0146","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.02.035_bib0152","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0153","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0154","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-021-01024-y","article-title":"Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction","volume":"60","author":"Ruehs","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0147","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved EF (Socrates-PRESERVED) study","volume":"38","author":"Piescke","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0148","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.02.035_bib0149","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): A double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0156","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0157","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rational and design of the VITALITY-HFpEF trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0158","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0159","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction) trial","volume":"21","author":"Piescke","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0160","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0161","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0162","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.02.035_bib0163","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cardfail.2022.10.431","article-title":"Practical patient care considerations with use of vericiguat after worsening heart failure events","volume":"29","author":"Rao","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0164","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","article-title":"Vericiguat: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0165","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cardfail.2023.04.015","article-title":"Classification of heart failure events by severity: Insights from the VICTORIA trial","volume":"29","author":"Felker","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0166","unstructured":"O\u2019Connor CM, Rathwell S, Mehrotra DV, et al. Assessing benefit in patients with heart failure with reduced ejection fraction: Analysis of the VICTORIA trial using novel prognostic risk stratification [published August 28, 2025]. J Card Fail."},{"key":"10.1053\/j.jvca.2026.02.035_bib0167","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, sex, and outcome in heart failure with reduced EF: Insights from the VICTORIA trial","volume":"11","author":"Lam","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0168","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1002\/ehf2.15416","article-title":"Geographic variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial","volume":"12","author":"Westerhout","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0169","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","article-title":"Background medical therapy and clinical outcomes from the VICTORIA trial","volume":"16","author":"Ezekowitz","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0171","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: Insights from the VICTORIA trial","volume":"24","author":"Senni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0172","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial","volume":"10","author":"Lam","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.02.035_bib0173","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/CIRCULATIONAHA.121.056797","article-title":"Hemoglobin and clinical outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)","volume":"144","author":"Ezekowitz","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0174","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"Saldarriaga","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0175","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ejhf.2285","article-title":"Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"23","author":"Ponikowski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0176","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jchf.2024.05.007","article-title":"Vericiguat and cardiovascular outcomes in heart failure by baseline diabetes status: Insights from the VICTORIA trial","volume":"12","author":"Khan","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0177","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: Insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0178","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to vericiguat according to index heart failure event: Insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0179","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jchf.2023.12.005","article-title":"Recurrent hospitalizations and response to vericiguat in heart failure and reduced ejection fraction","volume":"12","author":"Mentz","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0180","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0181","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jchf.2022.04.015","article-title":"Sequential evaluation of NT-proBNP in heart failure: Insights into clinical outcomes and efficacy of vericiguat","volume":"10","author":"Armstrong","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0182","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0183","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/TCRM.S357422","article-title":"Vericiguat in heart failure with a reduced ejection fraction: Patient selection and special considerations","volume":"18","author":"Kassis-George","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"10.1053\/j.jvca.2026.02.035_bib0184","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/ehf2.14050","article-title":"Vericiguat and NT-proBNP in patients with heart failure and reduced ejection fraction: Analysis from the VICTORIA trial","volume":"9","author":"Senni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0185","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010661","article-title":"Evolution of NT-proBNP during prerandomization screening in VICTORIA: Implications for clinical outcomes and efficacy of vericiguat","volume":"16","author":"Armstrong","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0186","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cardfail.2022.12.013","article-title":"Assessment of biomarkers of myocardial injury, inflammation, and renal function in heart failure with reduced ejection fraction: The VICTORIA biomarker substudy","volume":"29","author":"Defilippi","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0187","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy","volume":"25","author":"Piescke","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0188","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.2883","article-title":"Cardiac reverse remodeling with vericiguat: Victory or no victory?","volume":"25","author":"Khan","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0189","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jchf.2022.12.014","article-title":"Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA","volume":"11","author":"Butler","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0190","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cardfail.2021.06.019","article-title":"Representativeness of the VICTORIA trial population in clinical practice: Analysis of the PINNACLE registry","volume":"27","author":"Butler","year":"2021","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0191","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/ejhf.2939","article-title":"Eligibility for vericiguat in a real-world heart failure population to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry","volume":"25","author":"Nguyen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0192","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jchf.2022.11.007","article-title":"Applicability of vericiguat to patients hospitalized for heart failure in the United States","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0193","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s12325-021-01681-2","article-title":"Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event","volume":"38","author":"Alsumali","year":"2021","journal-title":"Adv Ther"},{"key":"10.1053\/j.jvca.2026.02.035_bib0194","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40273-021-01091-w","article-title":"Cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a US Medicare perspective","volume":"39","author":"Alsumali","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/j.jvca.2026.02.035_bib0195","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.122.063602","article-title":"Cost-effectiveness of vericiguat in patients with heart failure with reduced ejection fraction: The VICTORIA randomized clinical trial","volume":"148","author":"Chew","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.02.035_bib0196","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ehf2.15134","article-title":"Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial","volume":"12","author":"Kittipibul","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0197","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.3501","article-title":"Vericiguat global study in participants with chronic heart failure: Design of the VICTOR trial","volume":"27","author":"Reddy","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0198","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ejhf.3598","article-title":"Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial","volume":"27","author":"Saldarriaga","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0199","unstructured":"Docherty KF, McMurray JJV. Vericiguat: VICTORy or defeat? [published online November 7, 2025]. JACC Heart Fail."},{"key":"10.1053\/j.jvca.2026.02.035_bib0200","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/eurheartj\/ehaf655","article-title":"Vericiguat and mortality in heart failure and reduced ejection fraction: The VICTOR trial","volume":"47","author":"Butler","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0201","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/eurheartj\/ehaf888","article-title":"Vericiguat in heart failure with reduced ejection fraction: Being confident in the face of uncertainty","volume":"47","author":"Cannata","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.02.035_bib0202","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2025.08.051","article-title":"Effect of vericiguat on total heart failure events in compensated outpatients with HFrEF: Insights from VICTOR","volume":"86","author":"Zannad","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0203","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/ejhf.70033","article-title":"Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial","volume":"27","author":"Mentz","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0204","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: An individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0205","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0140-6736(25)01765-9","article-title":"Vericiguat across the heart failure spectrum","volume":"406","author":"Kohsaka","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.02.035_bib0206","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/ehf2.14802","article-title":"Evaluating haemodynamic changes: Vericiguat in patients with heart failure with reduced ejection fraction","volume":"11","author":"Suzuki","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0207","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132441","article-title":"Effectiveness of vericiguat on right ventricle to pulmonary artery uncoupling associated with heart failure with reduced ejection fraction","volume":"415","author":"Hashimoto","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0208","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/aor.14971","article-title":"Vericiguat experience in durable left ventricular assist device patients","volume":"49","author":"Elad","year":"2025","journal-title":"Artif Organs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0209","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2459\/JCM.0000000000001722","article-title":"Use of vericiguat in a heart transplant recipient with biventricular dysfunction","volume":"26","author":"Masarone","year":"2025","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1053\/j.jvca.2026.02.035_bib0211","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/ehf2.15186","article-title":"Vericiguat improves cardiac remodeling and function in rats with doxorubicin-induced cardiomyopathy","volume":"12","author":"Chen","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0212","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0213","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s40265-021-01586-y","article-title":"Drug treatment of heart failure with reduced ejection fraction: Defining the role of vericiguat","volume":"81","author":"Coats","year":"2021","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0214","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","article-title":"Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3","volume":"82","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl D","key":"10.1053\/j.jvca.2026.02.035_bib0215","doi-asserted-by":"crossref","first-page":"D278","DOI":"10.1093\/eurheartjsupp\/suad106","article-title":"ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy","volume":"25","author":"Di Fusco","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"10.1053\/j.jvca.2026.02.035_bib0216","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40256-024-00652-6","article-title":"Towards the fifth pillar for the treatment of heart failure with reduced ejection fraction: Vericiguat in older and complex patients","volume":"24","author":"Spadafora","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2026.02.035_bib0217","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cardfail.2022.04.015","article-title":"Epidemiology of worsening heart failure in a population-based cohort from Alberta, Canada: Evaluating eligibility for treatment with vericiguat","volume":"28","author":"Sepehrvand","year":"2022","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0218","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ehf2.14767","article-title":"Eligibility for vericiguat in a real-world, contemporary heart failure population","volume":"11","author":"Vergaro","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.02.035_bib0219","unstructured":"Victores A, Dash LD, Ru B, et al. Characterizing real-world use of vericiguat in the United States [published online August 19, 2025]. J Card Fail."},{"key":"10.1053\/j.jvca.2026.02.035_bib0220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00000542-199207000-00018","article-title":"Isoflurane does not vasodilate rat thoracic aortic rings by endothelium-derived relaxing factors or other cyclic GMP-mediated mechanisms","volume":"77","author":"Brendal","year":"1992","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2026.02.035_bib0221","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00000542-199407000-00027","article-title":"Nitric oxide does not mediate coronary vasodilation by isoflurane","volume":"81","author":"Crystal","year":"1994","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2026.02.035_bib0222","series-title":"Kaplan\u2019s cardiac anesthesia: Perioperative and critical care","first-page":"179","article-title":"Cardiovascular pharmacology of anesthetics","author":"Pagel","year":"2024"},{"key":"10.1053\/j.jvca.2026.02.035_bib0223","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0024-3205(94)00403-F","article-title":"Vascular effects of halothane and isoflurane: cGMP dependent and independent actions","volume":"56","author":"Jing","year":"1995","journal-title":"Life Sci"},{"key":"10.1053\/j.jvca.2026.02.035_bib0224","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(97)01491-X","article-title":"Halothane attenuates nitric oxide relaxation of rat aortas by competition for the nitric oxide receptor site on soluble guanylyl cyclase","volume":"342","author":"Jing","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.jvca.2026.02.035_bib0225","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1213\/00000539-199702000-00008","article-title":"Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels","volume":"84","author":"Park","year":"1997","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2026.02.035_bib0226","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cpt.2574","article-title":"Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: The randomized, phase Ib, VENICE study","volume":"111","author":"Boettcher","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2026.02.035_bib0227","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/cts.13238","article-title":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study","volume":"15","author":"Boettcher","year":"2022","journal-title":"Clin Transl Sci"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105307702600176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105307702600176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:06:55Z","timestamp":1778062015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105307702600176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":226,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S105307702600176X"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2026.02.035","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2026.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}